Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

China Sky One Pays $2.2 Million for Nine New Drugs

publication date: Nov 13, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Sky One Medical, Inc. (中国天字一号医药公司) has obtained the rights to nine new drugs from Shandong Medicine Research & Development Institute, paying 15 million RMB ($2.2 million). The company estimates the nine products will generate $5 million in revenue during 2009. According to China Sky One, the nine products are popular in rural areas of China and have received all necessary SFDA approvals. More details...

Stock Symbol: (NSDQ: CSKI)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...